Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 21;11(20):6217.
doi: 10.3390/jcm11206217.

Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients

Natalia Estrada  1 , Lurdes Zamora  1 , Francisca Ferrer-Marín  2 , Laura Palomo  3   4 , Olga García  1 , Patricia Vélez  5 , Iris De la Fuente  6 , Miguel Sagüés  6 , Marta Cabezón  1 , Montserrat Cortés  7 , Rolando Omar Vallansot  8 , María Alicia Senín-Magán  5 , Concepción Boqué  5 , Blanca Xicoy  1
Affiliations

Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients

Natalia Estrada et al. J Clin Med. .

Abstract

Imatinib is the most common first-line tyrosine kinase inhibitor (TKI) used to treat chronic-phase chronic myeloid leukemia (CP-CML). However, only a proportion of patients achieve major molecular response (MMR), so there is a need to find biological factors that aid the selection of the optimal therapeutic strategy (imatinib vs. more potent second-generation TKIs). The aim of this retrospective study was to understand the contribution of germline single-nucleotide variants (gSNVs) in the achievement of MMR with imatinib. In particular, a discovery cohort including 45 CP-CML patients was analyzed through the DMET array, which interrogates 1936 variants in 231 genes related to the absorption, distribution, metabolism and excretion (ADME) process. Variants statistically significant in the discovery cohort were then tested in an extended and independent cohort of 137 CP-CML patients. Finally, a total of 7 gSNVs (ABCG1-rs492338, ABCB11-rs496550, ABCB11-rs497692, CYP2D6-rs1135840, CYP11B1-rs7003319, MAT1A-rs4934027 and SLC22A1-rs628031) and one haplotype in the ABCB11 gene were significantly associated with the achievement of MMR with first-line imatinibtreatment. In conclusion, we identified a genetic signature of response to imatinib in CP-CML patients that could be useful in selecting those patients that may benefit from starting imatinib as first-line therapy, therefore avoiding the toxicity related to second-generation TKIs.

Keywords: chronic myeloid leukemia; imatinib; major molecular response; single-nucleotide polymorphisms.

PubMed Disclaimer

Conflict of interest statement

B.X. and L.Z. have received a grant from Novartis. F.F.M. has received a grant from Incyte. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript or in the decision to publish the results. The rest of the authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart describing genetic marker selection. ADME: adsorption, distribution, metabolism and excretion; MAF: minor allele frequency. gSNV: germline single-nucleotide variant.
Figure 2
Figure 2
Cumulative incidence (95% CI) of MMR for the gSNVs with p-value < 0.05. (A) 95% CI of MMR for rs492338 (ABCG1) for each of the three genotypes. (B) 95% CI of MMR for rs628031 (SLC22A1) grouped by recessive model. (C,D) 95% CI of MMR for rs4934027 (MAT1A) for each of the genotypes and grouped by dominant model. (E,F) 95% of MMR for rs1065852 (CYP2D6) for each of the genotypes and grouped by recessive model.
Figure 3
Figure 3
Haploview linkage disequilibrium graph. A total of 10 haplotype blocks were identified (A–D). Block 9 (D) was the only one statistically associated with the achievement of MMR with imatinib.
See this image and copyright information in PMC

References

    1. Mahon F.X. Treatment-free remission in CML: Who, how, and why? Hematol. Am. Soc. Hematol. Educ. Program. 2017;1:102–109. doi: 10.1182/asheducation-2017.1.102. - DOI - PMC - PubMed
    1. Hochhaus A., Baccarani M., Silver R.T., Schiffer C., Apperley J.F., Cervantes F., Clark R.E., Cortes J.E., Deininger M.W., Guilhot F., et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–984. doi: 10.1038/s41375-020-0776-2. - DOI - PMC - PubMed
    1. Etienne G., Dulucq S., Huguet F., Schmitt A., Lascaux A., Hayette S., Fort M.P., Sujobert P., Bijou F., Morisset S., et al. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors. Cancer Med. 2019;8:5173–5182. doi: 10.1002/cam4.2410. - DOI - PMC - PubMed
    1. Soverini S., Branford S., Nicolini F.E., Talpaz M., Deininger M.W., Martinelli G., Müller M.C., Radich J.P., Shah N.P. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk. Res. 2014;38:10–20. doi: 10.1016/j.leukres.2013.09.011. - DOI - PubMed
    1. Ma Q., Lu A.Y. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev. 2011;63:437–459. doi: 10.1124/pr.110.003533. - DOI - PubMed